newsfilter
← Latest News
GlobeNewswire·

eFFECTOR Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

Plan to present data at ASCO 2022 from ongoing zotatifin Phase 1/2 dose escalation and expansion trial Intend to provide an update on expanded development of zotatifin SAN DIEGO and REDWOOD CITY, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- eFFECTOR